Liposarcoma — Trials · CancerIndex

Clinical trials

Registered studies

136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 50
Recruiting: 25
Ph III recruiting: 2
Growth YoY: —
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06422806	Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	recruiting	Phase 3	365	National Cancer Institute (NCI)NIH	3	Sep 22, 2026	clinicaltrials
NCT07823491	Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall	not yet recruiting	Phase 3	228	Ohio State University Comprehensive Cancer CenterOTHER